Can Aurora Cannabis (TSX:ACB) Stock Rebound in 2020? 

Aurora Cannabis (TSX:ACB)(NYSE:ACB) stock could move higher on account of a low valuation, cash on the books and cannabis 2.0.

| More on:
question marks written reminders tickets

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Similar to nearly every other weed stock, Aurora Cannabis (TSX:ACB)(NYSE:ACB) has plummeted this year. The company has shed nearly two-thirds of its market value and is now trading at a two-year low. 

The reason for this is clear: the first full year of legal marijuana sales in Canada haven’t worked out as anyone expected. 

The new producers haven’t displaced the illegal pot industry as much as expected; some have even lost their licenses for selling pot illegally from legal facilities, well-known founders have been ousted, provinces like Ontario have actually lost money through distribution and reported sales have come in lower than expected this year. 

As one of the largest producers, Aurora has been fully exposed to this sudden shift in investor sentiment. But could the company see a turnaround next year? Here are two factors that could push the company’s stock higher in 2020:

Cannabis 2.0

At the moment, the legal marijuana sector operates as an agribusiness. Operations are focused on production capacity and the cost per gram of dry weed, similar to the way wheat or corn producers operate. 

However, this lack of differentiation is expected to fade away as producers launch brands and products that consumers can easily identify and stay loyal to. The imminent launch of edibles in Canada, now known as Cannabis 2.0, gives major producers like Aurora a chance to offer a wider variety of products with better margins. 

Earlier this year, the company announced it would begin producing edible products including baked goods, chocolates, mints, and infused beverages at a new Edmonton facility. Products are expected to be on the shelves by early 2020, and the added value to be reflected on the balance sheet next year. 

Low valuation

Like a tightly wound-up spring, ACB stock’s valuation has been suppressed too far. The company’s current market value is just 16 times cash and cash equivalents and 16% higher than book value per share. 

Property, plant and equipment are worth nearly $765 million, or 15% of total assets. Meanwhile, total debt is also under 15% of equity. 

That said, much of the company’s book value is concentrated in intangible assets like goodwill and the business is expected to remain cash flow negative for the next few years. But if the company can raise more cash through debt or equity issuance, the stock could unlock more value next year. 

In fact, similar to its rivals Cronos Group and Canopy Growth, securing a major strategic partner, could add some serious value for Aurora shareholders in the short-term. 

Eventually, as the industry matures, Aurora’s operations should become profitable as well. As it’s already one of the largest players, a culling of the competition in the current market shake-out is to Aurora’s benefit.

Bottom line

The ongoing chaos in the marijuana sector has pummelled valuations across the board. Investors can still expect plenty of wealth destruction in this sector over the next few years. 

However, major producers like Aurora Cannabis with enough resources, robust production networks and room to expand into new higher-margin categories such as edibles could emerge as winners in 2020 and beyond.  

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Vishesh Raisinghani has no position in any stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »